Introduction
Growth hormone is a diabetogenic hormone and there is now evidence that prolactin has similar diabetogenic properties (Landgraf et al., 1975 (Landgraf et al., , 1977 Woolf et al., 1977) . The ergot alkaloid, bromocriptine has been shown to improve glucose tolerance in patients with acromegaly and diabetes, and in some cases this improvement has occurred without changes in growth hormone levels. Various explanations have been offered for this phenomenon (Thorner et al., 1975; Besser et al., 1976; Camanni et al., 1975) .
The authors studied the effects of bromocriptine on glucose tolerance in patients with maturity onset diabetes and in normal subjects. As bromocriptine * Present address: Diabetic Unit, King's College Hospital, Denmark Hill, London SE5 9RS is a dopamine agonist, they also examined the effects on glucose tolerance of a dopamine antagonist, metoclopramide.
Patients and methods
Eight patients with maturity onset diabetes (5 female), and 6 normal subjects (5 male), were studied. The diabetics were all controlled on diet with or without oral hypoglycaemic therapy, and the normal subjects had normal glucose tolerance. The 
Results Glucose
The normal subjects all had normal glucose tolerance. After bromocriptine the plasma glucose curve was flattened with a significant reduction at 15 min, and a significant increase at 120 min when compared with the controls (Fig. la) .
Seven of the 8 diabetics, all of whom had impaired control curves, showed a marked improvement in glucose tolerance after bromocriptine. This improvement was maintained throughout the time of testing although it was not significant at 150 and 180 min. There was also a significant reduction of fasting blood glucose (Fig. la) .
After metoclopramide there was a significant impairment of glucose tolerance in the control subjects at 15 and 60 min (P <0.01), but no significant difference after this time. There was no significant effect in the diabetics (Fig. ib) .
Insulin
Plasma insulin was initially reduced in the diabetics after bromocriptine, although not significantly, at 120, 150 and 180 min (Fig. 2) . There was an initial lowering also in the normal subjects (P <0.05) but later the values were comparable to those obtained without bromocriptine. Metoclopramide had no significant effect on plasma insulin.
Prolactin
There was a marked fall in plasma prolactin after bromocriptine administration in both diabetic and normal subjects and this persisted throughout the time of the test (Fig. 3) .
Prolactin showed a significant rise after metoclopramide in both diabetic and normal subjects et al., 1972; Tolis, Pinter and Friesen, 1975; Gnudi, Lugori and Cavazzini, 1977) . Hyperprolactinaemia from any cause has been shown to decrease glucose tolerance and increase insulin response (Landgraf et al., 1977) . Suppression of basal prolactin concentration by bromocriptine may improve glucose tolerance and normalize glucose induced insulin release (Landgraf et al., 1977; Gnudi et al., 1977) . These findings are similar to the observations of the present authors-bromocriptine, a dopamine agonist, improves glucose tolerance and lowers prolactin, whereas metaclopramide, a dopamine antagonist, tends to impair the glucose profile (significantly in the normal subjects) and raises prolactin levels. Prolactin may play an important role in the glucose homoeostasis of the body, and indeed it is known to increase during hypoglycaemia. The present findings would support the hypothesis (Landgraf et al., 1975 (Landgraf et al., , 1977 Woolf et al., 1977) that prolactin is a diabetogenic hormone. The effect of bromocriptine on growth hormone was inconsistent, 4 out of 6 normal subjects responded markedly to bromocriptine with growth hormone release, but 2 failed to respond at all. The growth hormone response to bromocriptine may be the result of dopamine-like activity at the hypothalamic level. In the maturity onset diabetics, there was no effect on growth hormone after glucose, with or without bromocriptine or metoclopramide. These remained within the accepted basal range. In contrast, in studies carried out on insulin-dependent diabetics (Gnudi et al., 1977) basal growth hormone concentration was high and there was only partial suppression after oral glucose. Bromocriptine failed to suppress and, in fact, increased the growth hormone concentration.
A significant lowering of plasma prolactin, after bromocriptine, has been demonstrated in insulindependent diabetics (Gnudi et al., 1977) . This was accompanied by an apparent improvement in glucose tolerance, although this was not statistically significant. In the insulin-dependent diabetics studied, however, there was a rise in the already high serum growth hormone. This difference may explain why the improvement in glucose tolerance in maturity onset diabetics is much more marked than in the insulin-dependent diabetics.
To counter a possible criticism that the hypoglycaemic properties of bromocriptine demonstrated may be due to slowed stomach emptying, rather than changes in hormone profile, the authors also measured the effect of bromocriptine on intravenous glucose tolerance tests in different maturity onset diabetics. The 7 subjects showed an improvement in glucose tolerance, markedly so in 4 cases. If bromocriptine has any effect on glucose tolerance by reducing stomach emptying, this effect is not marked.
It is concluded that bromocriptine has a hypoglycaemic action in maturity onset diabetics, and this may be due to a lowering of prolactin concentration which occurs without a concomitant increase in growth hormone concentration. The concept of prolactin being a diabetogenic hormone is supported.
